
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed is a biopharmaceutical company with a robust commercial portfolio and promising clinical pipeline focused on respiratory, immunology, and rare neurological disorders. Despite concerns about headwinds in the near term, the company's two commercial products, Arikayce and Brinsupri, show strong demand and robust new patient starts, and management expects continued growth. With a potential market opportunity of over $10B, we believe Insmed is well-positioned to drive value for investors and its recent 1Q 2026 earnings report reinforces this positive outlook.
Bears say
Insmed is a biopharmaceutical company with a focus on respiratory, immunology, and rare neuro diseases. While the company has two approved commercial products and a robust pipeline, issues with access and adverse events are negatively impacting their success. Additionally, reliance on the success of one drug and competition in the market pose risks to their revenue potential.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares